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onOxidativeMetabolism of Benzo[a]Pyrene in
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1Department of Biochemistry, Faculty of Science, Charles University, Prague,
Czech Republic
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Benzo[a]pyrene (BaP) is a human carcinogen that
covalently binds to DNA after metabolic activation by
cytochrome P450 (CYP) enzymes. In this study human
recombinant CYPs (CYP1A1, 1A2, 1B1, 2A6, 2B6,
2C8, 2C9, 2C19, 2E1, 3A4, and 3A5) were
expressed in SupersomesTM together with their reduc-
tases, NADPH:CYP oxidoreductase, epoxide hydro-
lase and cytochrome b5, to investigate BaP
metabolism. Human CYPs produced up to eight BaP
metabolites. Among these, BaP-7,8-dihydrodiol and
BaP-9-ol, which are intermediates in BaP-derived DNA
adduct formation, were mainly formed by CYP1A1
and 1B1, and to a lesser extent by CYP2C19 and
3A4. BaP-3-ol, a metabolite that is a ‘detoxified’ prod-
uct of BaP, was formed by most human CYPs tested,
although CYP1A1 and 1B1 produced it the most effi-
ciently. Based on the amounts of the individual BaP
metabolites formed by these CYPs and their expression
levels in human liver, we determined their contributions
to BaP metabolite formation in this organ. Our results
indicate that hepatic CYP1A1 and CYP2C19 are most
important in the activation of BaP to BaP-7,8-
dihydrodiol, whereas CYP2C19, 3A4, and 1A1 are
the major enzymes contributing to the formation of
BaP-9-ol. BaP-3-ol is predominantly formed by hepatic
CYP3A4, while CYP1A1 and 2C19 are less
active. Environ. Mol. Mutagen. 57:229–235,
2016. VC 2016 The Authors. Environmental and Molecular
Mutagenesis Published byWiley Periodicals, Inc.
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INTRODUCTION
Benzo[a]pyrene (BaP) is a polycyclic aromatic hydrocarbon
(PAH) that has been classified as a human carcinogen (Group
1) by the International Agency for Research on Cancer [IARC,
2010]. BaP requires metabolic activation catalyzed by cyto-
chrome P450 (CYP) enzymes prior to reaction with DNA
[Baird et al., 2005]. The concentration of BaP in organisms is
crucial for the induction of malignant transformations initiated
by activated BaP. In addition to the total amount of ingested
BaP, metabolism dictates its effective concentration, which
thereby modulates BaP (geno)toxicity. BaP (geno)toxicity is
also modulated by a number of confounding factors including
other environmental pollutants (such as PAHs), human health
status, diets, etc. [IARC, 2010]. Nevertheless, the identification
of enzymes principally involved in BaP metabolism in humans
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and detailed knowledge of their catalytic specificities is of
major importance.
CYP1A1 is one of the most important CYP enzymes in
BaP bioactivation to species forming DNA adducts [Baird
et al., 2005], in combination with microsomal epoxide hydro-
lase (mEH). First, CYP1A1 oxidizes BaP to an epoxide,
which is then converted to BaP-7,8-dihydrodiol by mEH. Fur-
ther bioactivation by CYP1A1 leads to the ultimately reactive
species, BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) that can
react with DNA to form adducts preferentially at guanine resi-
dues (Supporting Information Fig. 1). The major product of
the reaction of BPDE with DNA in vitro and in vivo is the
adduct 10-(deoxyguanosin-N2-yl)27,8,9-trihydroxy-7,8,9,10-
tetrahydrobenzo[a]pyrene (dG-N2-BPDE) [Bauer et al., 1995;
Arlt et al., 2008, 2015; Kucab et al., 2015]. However, BaP is
also oxidized to other metabolites such as other dihydrodiols,
BaP-diones and hydroxylated metabolites [Bauer et al., 1995;
Kim et al., 1998; Baird et al., 2005; Jiang et al., 2007]. While
most of these metabolites are detoxification products, BaP-9-
ol is a precursor of 9-hydroxy-BaP-4,5-epoxide, which can
also form an adduct with deoxyguanosine in DNA (Support-
ing Information Fig. 1) [Stiborova et al., 2014].
CYP1B1 also oxidizes BaP, although its efficiency is about
half of that of CYP1A1 [Kim et al., 1998]. Among other CYP
enzymes, CYP1A2, 2C8, 2C9, 2C19, and 3A4 have all been
reported to oxidize BaP, but their efficiencies are more than
one order of magnitude lower than CYP1A1 [Bauer et al.,
1995; Kim et al., 1998; Baird et al., 2005]. However, little is
known about the impact of individual CYP enzymes on BaP
metabolism in human tissues, which is crucial to understand-
ing the carcinogenicity of BaP [IARC, 2010]. Lung, skin,
stomach, and to a lesser extent, liver, are targets for BaP carci-
nogenicity. These organs all contain enzymes that metabolize
xenobiotics including BaP. In this study, we evaluated the
contributions of individual CYP enzymes expressed in human
liver to BaP metabolism. We utilized human recombinant
CYPs expressed in microsomes of baculovirus-infected insect
cells (SupersomesTM) with their reductase NADPH:CYP oxi-
doreductase (POR) and mEH in the presence and absence of
cytochrome b5, a known modulator of enzymatic activity of
several CYPs [Porter, 2002; Schenkman and Jansson, 2003;
Stiborova et al., 2006; McLaughlin et al., 2010; Kotrbova
et al., 2011; Henderson et al., 2013; Stiborova et al., 2014].
To identify the contributions of individual hepatic CYPs to
BaP metabolism, the formation of BaP metabolites by indi-
vidual human CYPs was determined by HPLC analysis and
correlation with associated CYP enzyme expression levels in
human livers was investigated.
MATERIALS ANDMETHODS
Chemicals
BaP (CAS no. 50-32-8; purity 96%) was obtained from Sigma
Chemical Co (St. Louis, MO, USA).
Isolation of Cytochrome b5
Cytochrome b5 was isolated from rabbit liver microsomes as
described previously [Stiborova et al., 2014] and used for the reconstitu-
tion experiments.
Enzymatic Incubations
SupersomesTM are microsomes isolated from insect cells that have
been transfected with a baculovirus construct containing cDNA of
human CYPs (CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2E1,
3A4, and 3A5), and which also express POR, mEH and/or cytochrome
b5. Supersomes
TMwere purchased from Gentest Corp. (Woburn, MI,
USA) and were used to study BaP oxidation. Incubation mixtures con-
tained 100 mM potassium phosphate buffer (pH 7.4), NADPH-
generating system (1 mM NADP1, 10 mM D-glucose-6-phosphate, 1 U/
ml D-glucose-6-phosphate dehydrogenase), 100 nM human CYPs in
SupersomesTM, and 50 lM BaP (dissolved in 5 ll dimethyl sulfoxide) in
a final volume of 500 ll. As SupersomesTM expressing CYP1A1, 1A2,
and 1B1 did not contain cytochrome b5, the supersomal system was
reconstituted with purified cytochrome b5, isolated as described above.
Enzyme reconstitution utilizing these CYP systems in SupersomesTM
and purified cytochrome b5 was performed as described elsewhere [Sti-
borova et al., 2002, 2005, 2006; Kotrbova et al., 2011; Indra et al.,
2014; Stiborova et al. 2014], using a molar ratio of CYPs to cytochrome
b5 of 1:5. The reaction was initiated by adding 50 ll of the NADPH-
generating system. Control incubations were carried out either without
the enzymatic system (the CYP systems), or without the NADPH-
generating system, or without BaP. After incubation (378C, 20 min),
5 ll of 1 mM phenacetin (Sigma) in methanol was added as an internal
standard. BaP metabolites were extracted twice with ethyl acetate
(2 3 1 ml), after which the solvent was evaporated to dryness, with the
remaining residues dissolved in 25 ll methanol, followed by separation
of BaP metabolites by HPLC. BaP metabolite peaks were collected and
analyzed by NMR and/or mass spectrometry [Stiborova et al., 2014].
Further details on the methods are given in Supporting Information.
HPLC Analysis of BaPMetabolites
HPLC analysis of BaP metabolites was carried out as described [Sti-
borova et al., 2014]. BaP metabolite peaks (Supporting Information Fig.
2) were collected and analyzed by NMR and/or mass spectrometry as
reported [Stiborova et al., 2014]. The peak areas at 254 nm were calcu-
lated relative to the peak area of the internal standard phenacetin, and
expressed as relative peak areas.
Contributions of Human CYP Enzymes to the Formation
of BaP-7,8-Dihydrodiol, BaP-9-Ol, and BaP-3-Ol in
Human Liver
In order to calculate the contributions of individual CYPs to the for-
mation of BaP-7,8-dihydrodiol, BaP-9-ol, and BaP-3-ol in human livers,
we measured the velocities of their formation by the Supersomal CYP
enzyme systems containing cytochrome b5 (compare Fig. 2), and com-
bined these velocities with data on the average expression levels of indi-
vidual CYPs in human livers derived from our earlier studies on
CYP1A1 [Stiborova et al., 2002, 2005], or from Rendic and Di Carlo
[1997]. Specifically, the contributions of each CYP to BaP metabolite
formation in liver were calculated by dividing the relative metabolite-
forming activity of each CYP [r.a.cypi] (rate of formation of BaP-7,8-
dihydrodiol, BaP-9-ol, and BaP-3-ol multiplied by amounts of this CYP
in human liver) by the total relative activities (+[r.a.cypi]) of all
metabolite-forming CYPs. CYP3A4 is the most highly expressed CYP
in human liver (30% of the CYP hepatic complement), followed by
CYP2C9 and 1A2 (15 and 13%, respectively), while CYP2C19, 2E1
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2A6, 2D6, 2C8, and 3A5 each represent between 8.5 and 2.5% of
liver CYPs [Rendic and Di Carlo, 1997]. Finally, a low but detectable
amount of CYP2B6 is also expressed in human liver (0.2% of liver
CYPs). CYP1A1 and particularly CYP1B1 are both considered to be
extrahepatic CYP enzymes, although their expression in human liver can
be induced by various chemicals, resulting in them constituting <0.7%
and <0.1% of the liver CYP complement, respectively [Rendic and
DiCarlo, 1997; Stiborova et al., 2002, 2005].
RESULTS ANDDISCUSSION
Oxidation of BaP by Human Recombinant CYPs in
SupersomesTM
The metabolism of PAHs has been intensively studied
over the past decades [Baird et al., 2005], and various
studies have examined the roles of individual human
CYPs (particularly CYP1A1 and CYP1B1) to metabolize
BaP in several enzyme systems [Bauer et al., 1995; Kim
et al., 1998; Baird et al., 2005; Indra et al., 2014; Stibor-
ova et al., 2014]. However, previous studies often used
CYP systems that do not fully correspond to the natural
enzyme system located in the membrane of the endoplas-
mic reticulum (microsomes), as cytochrome b5 (a known
modulator of enzymatic activity of several CYPs [Porter,
2002; Schenkman and Jansson, 2003; Stiborova et al.,
2006; Kotrbova et al., 2011; McLaughlin et al., 2010; Sti-
borova et al., 2014]) was not incorporated. In order to
better model hepatic microsomes, we utilized enzyme sys-
tems containing microsomes (SupersomesTM) together
with human CYPs (CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8,
2C9, 2C19, 2E1, 3A4, and 3A5), POR, mEH, and cyto-
chrome b5. Cytochrome b5 was either expressed in Super-
somesTM together with CYPs, POR, and mEH, or
SupersomesTM were reconstituted with purified cyto-
chrome b5. These CYP enzyme systems efficiently oxi-
dized their typical substrates (data not shown). The BaP
metabolite profile formed by individual human CYPs in
SupersomesTM was determined by HPLC analysis, and
BaP metabolites were identified by NMR and/or mass
spectrometry as described previously [Stiborova et al.,
2014].
Up to eight BaP metabolites were separated by HPLC
using the CYP enzyme systems (Supporting Information
Fig. 2): BaP-9,10-dihydrodiol (M1), BaP-4,5-dihydrodiol
(M2), BaP-7,8-dihydrodiol (M3), BaP-1,6-dione (M4),
BaP-3,6-dione (M5), BaP-9-ol (M6), BaP-3-ol (M7), and
a metabolite of unknown structure (Mx). When the
NADPH-generating system was omitted from the incuba-
tion mixtures, essentially no BaP metabolites were formed
(data not shown). Amounts of the various BaP metabo-
lites formed were dependent on the individual CYP isoen-
zyme studied (Figs. 1 and 2).
Of the human recombinant CYPs tested in these enzy-
matic systems, CYP1A2, 2A6, 2C8, and 2E1 did not cata-
lyze BaP oxidation (Fig. 1). It should be noted that
contrasting results have been found with regards to the
role of human CYP1A2 in BaP oxidation. Whereas some
studies found that human CYP1A2 partially oxidized BaP
[Bauer et al. 1995; Kim et al. 1997], other studies reported
that human CYP1A2 is not effective in mediating BaP
hydroxylation [Endo et al. 2008]. In our system, CYP1A1
had the highest BaP-metabolizing potency, followed by
CYP1B1, 2C19, 3A4, 2B6, 2C9, and 3A5 (Fig. 1).
Of the BaP metabolites generated by the CYP enzyme
systems, BaP-3-ol was formed by most of the CYPs
active in BaP metabolism as the major BaP oxidation
product, except CYP1B1 (Fig. 2). This BaP oxidation
product is considered to be a detoxification metabolite
[Huang et al., 1996]. In addition, BaP-7,8-dihydrodiol and
BaP-9-ol were formed (Fig. 2), which are precursors of
BPDE and 9-hydroxy-BaP-4,5-oxide respectively, both of
which covalently bind to DNA forming adducts (see Sup-
porting Information Fig. 1). Of the CYPs tested here,
CYP1A1, 1B1, and CYP2C19 were capable of forming
BaP-7,8-dihydrodiol (Fig. 2). The formation of BaP-9-ol
was also mainly catalyzed by CYP1A1 and 1B1, while
CYP2C19 and CYP3A produced this metabolite to a
lesser extent (Fig. 2). CYP1A1 and 1B1 were also the
most effective in catalyzing oxidation of BaP to BaP-3-ol,
although this metabolite was also formed by CYP2B6,
2C9, 2C19, and 3A4/5 (Fig. 2).
Interestingly, we found that cytochrome b5 strongly
modulated the activity of some CYPs to metabolize BaP,
most notably CYP1A1 (Fig. 3). The CYP1A1 enzyme
system generated the largest amount of BaP-3-ol (Fig.
3A). Addition of cytochrome b5 to CYP1A1 in Superso-
mesTM increased BaP oxidation to this metabolite more
than twofold. The greatest stimulatory effect of cyto-
chrome b5 was in the formation of BaP-3-ol and BaP-7,8-
Fig. 1. BaP metabolism catalyzed by individual human CYPs expressed
in SupersomesTM in the presence of cytochrome b5 (b5). Columns show
the sum of individual BaP metabolites formed by CYPs. Data shown are
averages and standard deviation from three independent measurements.
ND, not detected.
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dihydrodiol, and to a lesser extent on the other BaP
metabolites produced (Fig. 3A). Overall, in the enzyme
system used, human CYP1A1 metabolized BaP to seven
metabolites: BaP-7,8-dihydrodiol, BaP-9,10-dihydrodiol,
BaP-1,6-dione, BaP-3,6-dione, BaP-3-ol, BaP-9-ol, and
the metabolite Mx (Figs. 2 and 3A). In contrast, BaP-4,5-
dihydrodiol was not detected in the CYP1A1 system
(Figs. 2 and 3A) which is consistent with previous find-
ings showing that this BaP metabolite was also not
formed in human bronchoalveolar H358 cells expressing
CYP1A1 exposed to BaP [Jiang et al., 2007].
Sudan I and 7-ethoxyresorufin are both used as markers
for CYP1A enzyme activity. Interestingly, cytochrome b5
has been previously shown to stimulate CYP1A1-
mediated oxidation of Sudan I [Stiborova et al., 2002,
2005, 2006] but not 7-ethoxyresorufin [Stiborova et al.,
2005, 2006]. Similarly, we have previously shown that
cytochrome b5 impacts CYP1A1-mediated metabolism of
the anticancer drug ellipticine [Kotrbova et al., 2011].
Two mechanisms have been suggested to describe how
cytochrome b5 modulates CYP catalysis: 1) it can affect
CYP catalytic activities by donating the second electron
to CYP in a CYP catalytic cycle; and/or 2) it can act as
an allosteric modifier of the oxygenase [Porter, 2002;
Schenkman and Jansson, 2003; Guengerich, 2005; Kotr-
bova et al., 2011]. However, the mechanism(s) underlying
such allosteric effects, based on reports that apo-
cytochrome b5 can stimulate CYP catalysis, are still
uncertain at present. Nevertheless, it seems to be clear
that cytochrome b5 binding can cause conformational
changes to the substrate access channel and binding
pocket in the CYP enzyme [Porter, 2002; Estrada et al.,
2014]. Addition of cytochrome b5 to the CYP enzyme
system changed both the absolute amounts, and to a
lesser extent the relative amounts, of the individual BaP
metabolites formed by CYP1A1 (Fig. 3A). Thus, interac-
tion of CYP1A1 with cytochrome b5 could result both in
Fig. 2. Formation of BaP metabolites by human CYPs expressed in SupersomesTM in the presence of cytochrome b5
(b5). Data shown are averages and standard deviation from three independent measurements. ND, not detected.
Fig. 3. Oxidation of BaP by human recombinant CYP1A1 (A) and
CYP1B1 (B) expressed in SupersomesTM and the effect of cytochrome b5
(cyt b5) on this oxidation. Data shown are averages and standard devia-
tion from three independent measurements. ND, not detected. Comparison
was performed by Student t-test analysis; *P < 0.05, **P < 0.01,
***P < 0.001, different from CYP1A1-mediated oxidation of BaP with-
out cytochrome b5.
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conformational changes in the CYP1A1 protein molecule
and/or an impact on the electron transfer from cyto-
chrome b5 to CYP1A1, thereby providing mechanisms to
explain the observed increase in BaP oxidation. Neverthe-
less, further investigations are required to clarify the
mechanism responsible for the effects of cytochrome b5
on CYP1A1-mediated oxidation of BaP.
Human CYP1B1 oxidized BaP to the same metabolites
as CYP1A1 (Figs. 2 and 3B). As with CYP1A1, BaP-4,5-
dihydrodiol was not been detected in the CYP1B1
enzyme system. BaP-7,8-dihydrodiol was the major BaP
metabolite generated by CYP1B1. However, in contrast
to CYP1A1, addition of cytochrome b5 to the CYP1B1
enzyme system had no significant effect on BaP oxidation
(Fig. 3B).
Contributions of Individual CYPs to BaPMetabolism in
Human Liver
BaP-7,8-dihydrodiol, BaP-9-ol and BaP-3-ol are critical
intermediates that contribute to the (geno)toxicity of BaP.
Therefore, it is crucial to examine which of the CYP
enzymes expressed in human liver are most important for
the formation of these metabolites. Based on the amounts
of BaP-7,8-dihydrodiol, BaP-9-ol and BaP-3-ol formed by
each human CYP enzyme, and the expression levels of
these enzymes in human liver [Rendic and DiCarlo, 1997;
Stiborova et al., 2002, 2005], we estimated the contribu-
tions of individual CYPs to the formation of these BaP
metabolites in human liver.
Although CYP1A1 is expressed in human liver at very
low levels (<0.7%) [Rendic and DiCarlo, 1997; Stiborova
et al., 2002, 2005], it is estimated to form more BaP-7,8-
dihydrodiol than any other human CYP (48.3% of all
BaP-7,8-dihydrodiol synthesis) (Fig. 4A). A similar con-
tribution to the formation of BaP-7,8-dihydrodiol is attrib-
uted to CYP2C19 (47.9%), whereas CYP1B1
contributed little (3.8%) to its formation (Fig. 4A).
Other human hepatic CYPs have essentially no impact on
the formation of this metabolite.
For BaP-9-ol, the highest contribution to its formation
is attributed to CYP2C19 (35.5%), followed by
CYP3A4 (31.4%), and CYP1A1 (27.4%); in contrast,
CYP3A5 (4.7%) and CYP1B1 (1%) had minor
impacts on its formation (Fig. 4B). In human liver, the
formation of BaP-3-ol, which is the major metabolite
formed by most of the tested human CYP enzymes, is
attributed to CYP3A4 (52.8%), followed by CYP1A1
(26.7%) and CYP2C19 (14.3%). CYP2C9 (3.3%),
2B6 (2.1%), 3A5 (0.4%), and 1B1 (0.4%) also par-
ticipate in the formation of this detoxification BaP metab-
olite in human liver, but their contribution is minor (Fig.
4C). Other CYP enzymes expressed in human liver have
essentially no ability to form BaP-3-ol.
CONCLUSIONS
In the present study, we identified the human CYPs
expressed in a microsomal system (i.e. SupersomesTM)
that are most effective in BaP metabolism in the presence
of POR, mEH, and cytochrome b5. We showed that BaP
is metabolized to up to eight metabolites including the
activation metabolites BaP-7,8-dihydrodiol and BaP-9-ol,
and the detoxification metabolite BaP-3-ol. We showed
that BaP-7,8-dihydrodiol and BaP-9-ol are mainly formed
by CYP1A1 and 1B1, and to a lesser extent by CYP2C19
and CYP3A4. In contrast, the formation of BaP-3-ol is
most efficiently catalyzed by CYP1A1 and 1B1, but
CYP2B6, 2C9, 2C19, and 3A4 also partially contribute to
its production.
Based on amounts of BaP-7,8-dihydrodiol, BaP-3-ol,
and BaP-9-ol formed by individual human CYP enzymes,
and expression levels of CYPs in human liver, we deter-
mined the contributions of CYPs to their formation in
this human organ. However, it should be noted that actual
hepatic concentrations are also influenced by the phase II
enzymes [Shi et al., 2015] that were not evaluated in the
present study. In human liver CYP1A1 and CYP2C19 are
Fig. 4. Contributions of CYP enzymes to the formation BaP-7,8-
dihydrodiol (A), BaP-9-ol (B), and BaP-3-ol (C) in human livers.
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most important in the activation of BaP to BaP-7,8-
dihydrodiol, producing 48% of the total amount of this
metabolite; whereas, CYP2C19 (35%), 3A4 (31%), and
1A1 (26%) are the major enzymes contributing to the
formation of BaP-9-ol. The detoxification of BaP to
BaP-3-ol is predominantly catalyzed by hepatic
CYP3A4, the major CYP enzyme expressed in human
livers, contributing to more than 50% of its formation,
while CYP1A1 (27%) and 2C19 (14%) contribute to a
lesser extent.
Our study demonstrates that the degree of activation or
detoxification of BaP in human liver is affected by both
the activities of individual human CYPs to metabolize
BaP, and the expression levels of these CYP enzymes in
human. Therefore, modulation of levels and activities of
hepatic CYPs, mediated both by their polymorphisms (or
internal regulation), and their induction or inhibition by
endogenous and exogenous compounds, determines the
(geno)toxic properties of BaP. Approaches analogous to
those carried out in the present study might be utilized
for evaluating the contributions of human CYPs to BaP
metabolism in the lung, a target organ for BaP carcinoge-
nicity. However, as CYP expression levels in the human
lung have not yet been fully characterized, this remains a
challenge for future studies.
AUTHORCONTRIBUTIONS
M.S., E.F., H.H.S., and V.M.A. designed the study.
M.S., R.I., and M.M. performed the experiments, ana-
lyzed the data, and prepared the figures. M.S. and V.M.A.
prepared the manuscript draft and had complete access to
the study data. All authors approved the final manuscript.
REFERENCES
Arlt VM, Stiborova M, Henderson CJ, Thiemann M, Frei E, Aimova D,
Singhs R, da Costa GG, Schmitz OJ, Farmer PB, et al. 2008.
Metabolic activation of benzo[a]pyrene in vitro by hepatic cyto-
chrome P450 contrasts with detoxification in vivo: experiments
with hepatic cytochrome P450 reductase null mice. Carcinogene-
sis 29:656–665.
Arlt VM, Krais AM, Godschalk RW, Riffo-Vasquez Y, Mrizova I,
Roufosse CA, Corbin C, Shi Q, Frei E, Stiborova M, et al. 2015.
Pulmonary inflammation impacts on CYP1A1-mediated respira-
tory tract DNA damage induced by the carcinogenic air pollutant
benzo[a]pyrene. Toxicol Sci 146:213–225.
Baird WM, Hooven LA, Mahadevan B. 2005. Carcinogenic polycyclic
aromatic hydrocarbon-DNA adducts and mechanism of action.
Environ Mol Mutagen 45:106–114.
Bauer E, Guo Z, Ueng YF, Bell LC, Zeldin D, Guengerich FP. 1995.
Oxidation of benzo[a]pyrene by recombinant human cytochrome
P450 enzymes. Chem Res Toxicol 8:136–142.
Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR. 1998.
Development of a comprehensive panel of antibodies against the
major xenobiotic metabolising forms of cytochrome P450 in
humans. Biochem Pharmacol 56:377–387.
Endo K, Uno S, Seki T, Ariga T, Kusumi Y, Mitsumata M, Yamada S,
Makishima M. 2008. Inhibition of aryl hydrocarbon receptor
transactivation and DNA adduct formation by CYP1 isoform-
selective metabolic deactivation of benzo[a]pyrene. Toxicol Appl
Pharmacol 230:135–143.
Estrada DF, Skinner AL, Laurence JS, Scott EE. 2014. Human cyto-
chrome P450 17A1 conformational celection. J Biol Chem 289:
14310–14320.
Guengerich FP. 2005. Reduction of cytochrome b5 by NADPH-
cytochrome P450 reductase. Arch Biochem Biophys 440:204–
211.
Henderson CJ, McLaughlin LA, Wolf CR. 2013. Evidence that cyto-
chrome b5 and cytochrome b5 reductase can act as sole electron
donors to the hepatic cytochrome P450 system. Mol Pharmacol
83:1209–1217.
Huang MT, Wood AW, Chang RL, Yagi H, Sayer JM, Jerina DM,
Conney AH. 1986. Inhibitory effect of 3-hydroxybenzo(a)pyrene
on the mutagenicity and tumorigenicity of (1/2)-7 beta, 8 alpha-
dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10-tetrahydrobenzo(a)-
pyrene. Cancer Res 46:558–566.
Iarc 2010. International Agency for Research on Cancer. Some non-
heterocyclic polycyclic aromatic hydrocarbons and some
related exposures. IARC Monogr Eval Carcinog Risks Hum 92:
1–853.
Indra R, Moserova M, Kroftova N, Sulc M, Martinkova M, Adam V,
Eckschlager T, Kizek R, Arlt VM, Stiborova M. 2014. Modula-
tion of human cytochrome P450 1A1-mediated oxidation of ben-
zo[a]pyrene by NADPH:cytochrome P450 oxidoreductase and
cytochrome b5. Neuro Endocrinol Lett 35:105–113.
Jiang H, Gelhaus SL, Mangal D, Harvey RG, Blair IA, Penning TM.
2007. Metabolism of benzo[a]pyrene in human bronchoalveolar
H358 cells using liquid chromatography–mass spectrometry.
Chem Res Toxicol 20:1331–1341.
Kim JH, Stansbury KH, Walker NJ, Trush MA, Strickland PT, Sutter
TR. 1998. Metabolism of benzo[a]pyrene and benzo[a]pyrene-
7,8-diol by human cytochrome P450 1B1. Carcinogenesis 19:
1847–1853.
Kucab JE, van Steeg H, Luijten M, Schmeiser HH, White PA, Phillips
DH, Arlt VM. 2015. TP53 mutations induced by BPDE in Xpa-
WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo
fibroblasts. Mutat Res 773:48–62.
Kotrbova V, Mrazova B, Moserova M, Martinek V, Hodek P, Hudecek
J, Frei E, Stiborova M. 2011. Cytochrome b5 shifts oxidation of
the anticancer drug ellipticine by cytochromes P450 1A1 and
1A2 from its detoxication to activation, thereby modulating its
pharmacological efficacy. Biochem Pharmacol 82:669–680.
McLaughin LA, Ronseaux S, Finn RD, Henderson C and, Wolf CR.
2010. Deletion of microsomal cytochrome b5 profoundly affects
hepatic and extrahepatic drug metabolism. Mol Pharmacol 75:
269–278.
Porter TD. 2002. The roles of cytochrome b5 in cytochrome P450 reac-
tions. J Biochem Mol Toxicol 16:311–316.
Rendic S, Di Carlo FJ. 1997. Human cytochrome P450 enzymes: a sta-
tus report summarizing their reactions, substrates, inducers, and
inhibitors. Drug Metab Rev 29:413–580.
Schenkman JB, Jansson I. 2003. The many roles of cytochrome b5.
Pharmacol Ther 97:139–152.
Shi Q, Haenen GR, Maas L, Arlt VM, Spina D, Vasquez YR, Moonen
E, Veith C, Van Schooten FJ, Godschalk RW. Inflammation-
associated extracellular b-glucuronidase alters cellular responses
to the chemical carcinogen benzo[a]pyrene. Arch Toxicol (in
press). doi: 10.1007/s00204-015-1593-7.
Stiborova M, Martinek V, Rydlova H, Hodek P, Frei E. 2002. Sudan I
is a potential carcinogen for humans: Evidence for its
metabolic activation and detoxication by human recombinant
Environmental and Molecular Mutagenesis. DOI 10.1002/em
234 Sulc et al.
cytochrome P450 1A1 and liver microsomes. Cancer Res 62:
5678–5684.
Stiborova M, Martinek V, Rydlova H, Koblas T, Hodek P. 2005.
Expression of cytochrome P450 1A1 and its contribution to oxi-
dation of a potential human carcinogen 1-phenylazo-2-naphthol
(Sudan I) in human livers. Cancer Lett 220:145–154.
Stiborova M, Martinek V, Schmeiser HH, Frei E. 2006. Modulation of
CYP1A1-mediated oxidation of carcinogenic azo dye Sudan I
and its binding to DNA by cytochrome b5. Neurol Endocrinol
Lett 27(Suppl2):35–39.
Stiborova M, Moserova M, Cerna V, Indra R, Dracinsky M, Sulc M,
Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Frei E,
Arlt VM. 2014. Cytochrome b5 and epoxide hydrolase contribute
to benzo[a]pyrene–DNA adduct formation catalyzed by cyto-




Environmental and Molecular Mutagenesis. DOI 10.1002/em
Activation and Detoxification of Benzo[a]Pyrene by Human Cytochrome P450s 235
